1759P A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada Background: Cancer patients who continue to smoke gain less benefit from treatments, experience greater toxicities, are at increased risk of cancer recurrence and second primaries, experience poorer quality of life and decreased survival. Despite awareness of the negative health benefits of continued smoking after a diagnosis of cancer, a systematic approach to help newly diagnosed cancer patients in cancer centres to quit smoking is uncommon. Methods: In 2012, Cancer Care Ontario established a framework to implement smoking cessation (SC) in all 14 regional cancer centres (RCCs) in the province of Ontario, Canada. The Framework included: use of the 5A's (ask, advise, assess, assist, arrange), recruitment of regional champions to promote the program, and data collection to document that new ambulatory cancer patients were screened for smoking status, advised on the health benefits of cessation and recommended a referral for cessation support. Screening rates became a performance metric to drive implementation and were reviewed quarterly with provincial and regional leaders. During fiscal 2014/15, just over 50% of patients were screened for smoking status. Recent efforts to improve performance include the transition to the 3A's (ask, advise, act) model, using proportion of smokers accepting a referral for SC services as a performance metric, and use of an "opt-out" approach to referrals where tobacco users are automatically referred to cessation services. An environmental scan and site visits resulted in RCC site-specific improvement plans. Results: The majority of RCCs are exceeding the screening target of 70% (5 centres with proportions > 80%) but the proportion of smokers accepting a referral remains low. The opt-out referral approach is anticipated to increase referral rates and preliminary data are encouraging for centres that have transitioned to the opt-out approach. Conclusions: To improve program efficiency and impact, Cancer Care Ontario's provincial smoking cessation initiative has transitioned from a 5 to 3 A's model and introduced an opt-out referral process. Front-line staff are adopting the simplified approach and early results show a promising increase in the number of smokers accepting referrals for SC services. Legal entity responsible for the study: Cancer Care Ontario. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
1760P A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan, 2 Surgical Oncology, Nagoya University Hospital, Nagoya, Japan, 3 Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, Nagoya, Japan Background: Chemotherapy-induced peripheral neurotoxicity (CIPN) exacerbates cumulatively and dose-dependently. Assessment of CIPN usually depends on subjective grading scales, such as the Common Terminology Criteria for Adverse Events (CTCAE). We previously validated a newly developed point-of-care nerve conduction device (POCD) for the quantitative assessment of CIPN (Cancer Sci 2016). The aim of the present study was to prospectively assess CIPN using this POCD. Methods: Patients scheduled to receive 8 cycles of adjuvant CapeOX therapy (capecitabine and oxaliplatin) for colorectal cancer were enrolled. Sural nerve amplitude potentials (SNAP, lV), a quantitative measure of the axonal degeneration, and sural nerve conduction velocity (SNCV, m/s), that of the degree of demyelination, were recorded using a portable and automated POCD (DPN-CheckV R , Neurometrix Inc., Waltham, MA, USA) at baseline, each cycle of chemotherapy, and within 1 month after the end of chemotherapy. The severity of CIPN was evaluated according to the CTCAE. The total sum of SNAP/SNCV was calculated for each patient, and compared according to each CTCAE grade. Results: A total of 39 patients (M/F: 22/17; median age 61 years, range 36-76; worst CTCAE G1/G2/G3: 25/10/4) were enrolled. Mean SNAP/SNCV at baseline, each cycle of chemotherapy, and within 1 month after the end of chemotherapy are shown in the table. SNAP decreased significantly during each cycle of chemotherapy (repeated ANOVA, P < 0.001), whereas SNCV remained relatively unchanged. The mean total sum of SNAP was 112.6636.8 G1, 69.8619.2 G2, and 44.8612.8 G3. The mean total sum of SNCV was 451.1634.9 G1, 454.2624.7 G2, and 429.8630.1 G3. The total SNAP differed significantly among each CTCAE grade (ANOVA, P < 0.001), whereas the total SNCV did not. Conclusions: This POCD demonstrates SNAP-dominant neuropathy in patients who receive oxaliplatin, indicating axonal degeneration as a mechanism of CIPN. Clinical trial identification: UMIN000017868. Legal entity responsible for the study: Nagoya University Hospital. Background: Pain and fatigue are the major determinants of health-related quality of life (HRQOL) in cancer patients undergoing chemotherapy. Ovarian cancer is the seventh most common cause of cancer in women worldwide. PARP inhibitors maintenance has shown to improve survival in recurrent ovarian cancer patients with notable toxicities. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of HRQOL events and pulmonary toxicities. Methods: We conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through March 2018. Phase III RCTs that mention HRQOL events and pulmonary toxicities as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Fixed effects model was applied. 
